Health-related quality of life and symptom research in glioblastoma multiforme patients

References

• Macdonald DR, Kiebert G, Prados M, Yung A, Olson J. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest. 23, 138–144 (2005).
   PubMed Web of Science ®Google Scholar
• Sanders C, Egger M, Donovan J et al. Reporting on quality of life in randomised controlled trials: bibliographic study. Br. Med. J. 317, 1191–1194 (1998).
   PubMed Web of Science ®Google Scholar
• Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. Macleod CM (Ed.), Columbia University Press, NY, USA 191–205 (1949).
   Google Scholar
• Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. Lancet Oncol. 4, 11–12 (2003).
   PubMed Web of Science ®Google Scholar
• Aiken RD. Quality-of-life issues in patients with malignant gliomas. Sem. Oncol. 21, 273–275 (1994).
   PubMed Web of Science ®Google Scholar
• Heimans JJ, Taphoorn MJB. Impact of brain tumour treatment on quality of life. J. Neurol. 249, 955–960 (2002).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N. Engl. J. Med. 344, 114–123 (2001).
   PubMed Web of Science ®Google Scholar
• Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636–645 (2000).
   PubMed Web of Science ®Google Scholar
• Louis DN, Holland EG, Cairncross JG. Glioma classification: a molecular reappraisal. Am. J. Pathol. 159, 770–786 (2001).
   Google Scholar
• Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360–364 (1988).
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology 51, 1140–1145 (1998).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Bottomley A, Taphoorn MJ, Coens C et al. Predicting survival using health-related quality of life scores in glioblastoma cancer: findings from an international Phase III randomized controlled trial. 41th Annual Meeting of the American Society of Clinical Oncology (ASCO), FL, USA. J. Clin. Oncol. 23(16S), 861 (2003).
   Google Scholar
• Kleihues P, Cavenee WK. In: Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, France (2000).
   Google Scholar
• Davies E, Clarke C. Early symptoms of brain tumours. J. Neurol. Neurosurg. Psychiatry 75, 1205–1206 (2004).
   PubMed Web of Science ®Google Scholar
• Kreth FW, Berlis A, Spiropoulou V et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 86, 2117–2123 (1999).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323–1329 (1980).
   PubMed Web of Science ®Google Scholar
• Kristiansen K, Hagen S, Kolleveld T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. Cancer 47, 649–652 (1981).
   PubMed Web of Science ®Google Scholar
• Slotman BJ, Kralendonk JH, van Alphen HAM et al. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 34, 895–898 (1996).
   PubMed Web of Science ®Google Scholar
• Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 22, 1583–1588 (2004).
   Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 23, 1011–1018 (2002).
   Google Scholar
• Taphoorn MJB, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. (2005) (In Press).
   PubMedGoogle Scholar
• Straathof CS, van den Bent MJ, Schmitz PL et al. The effect of dexamethasone on the uptake of cisplatin in glioma and the area of brain around tumor. J. Neurooncol. 37, 1–8 (1998).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Wagner GL, Wilms EB. Interactions between anti-epileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404–409 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta T, Sarin R. Poor-prognosis high-grade gliomas: evolving an evidence-based standard care. Lancet Oncol. 3, 557–564 (2002).
   PubMed Web of Science ®Google Scholar
• Remer S, Murphy ME. The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin. J. Oncol. Nurs. 8, 368–376 (2004).
   PubMedGoogle Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three RTOG malignant glioma trials. J. Natl Cancer Instit. 85, 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Buckner JC. Factors influencing survival in high-grade gliomas. Semin. Oncol. 30, S19, 10–14 (2003).
   Google Scholar
• Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54, 1442–1448 (2000).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J. Clin. Oncol. 18, 646–650 (2000).
   PubMed Web of Science ®Google Scholar
• Klein M, Postma TJ, Taphoorn MJB et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61, 1796–1799 (2003).
   Google Scholar
• Sehlen S, Lenk M, Hollenhorst H et al. Quality of life as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 26, 38–43 (2003).
   PubMedGoogle Scholar
• Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 3, 159–168 (2004).
   PubMed Web of Science ®Google Scholar
• Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 55, 992–999 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson SW, Damasio H, Tranel D. Neuropsychological impairment associated with lesions caused by tumor or stroke. Arch. Neurol. 47, 397–405 (1990).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro. Oncol. 5, 89–95 (2003).
   PubMed Web of Science ®Google Scholar
• Klein M, Heimans JJ, Aaronson NK et al. Mid- to long-term cognitive sequelae in low-grade gliomas: the impact of radiotherapy and other treatment-related factors. Lancet 360, 1361–1368 (2002).
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC et al. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277–1280 (1990).
   PubMed Web of Science ®Google Scholar
• Clyde Z, Chataway SJ, Signorini D, Gregor A, Grant R. Significant change in tests of neurological impairment in patients with brain tumours. J. Neurooncol. 39, 81–90 (1998).
   PubMed Web of Science ®Google Scholar
• De Haan R, Limburg M, Schuling J et al. Clinimetric evaluation of the Barthel Index, a measure of limitations in daily activities. Ned. Tijdschr. Geneeskd. 137, 917–921 (1993).
   PubMedGoogle Scholar
• Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HC, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19, 604–607 (1988).
   PubMed Web of Science ®Google Scholar
• Aaronson NK. Quality of life: What is it? How should it be measured? Oncology 2, 69–74 (1988).
   PubMedGoogle Scholar
• Sprangers MA, Aaronson NK. The role of healthcare providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J. Clin. Epidemiol. 45, 743–760 (1992).
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J. Chron. Disease 34, 585–597 (1981).
   PubMedGoogle Scholar
• Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 272, 619–626 (1994).
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75, 1151–1161 (1995).
   PubMed Web of Science ®Google Scholar
• Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual. Life Res. 5, 139–150 (1996).
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A, EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC- the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 38, S4, 125–133 (2002).
   Google Scholar
• Fayers P, Aaronson N, Bjordal K et al. EORTC QLQ-C30 In: Scoring Manual, Third Edition. EORTC Publications, Belgium (2001).
   Google Scholar
• Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139–144 (1998).
   PubMed Web of Science ®Google Scholar
• Murray KJ, Nelson DF, Scott C et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation and carmustine: a report of RTOG 83–02. Int. J. Radiat. Oncol. Biol. Phys. 31, 453–459 (1995).
   PubMed Web of Science ®Google Scholar
• Recht L, Glantz M, Chamberlain M, Hsieh CC. Quantative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective chart. J. Neurooncol. 61, 127–136 (2003).
   PubMed Web of Science ®Google Scholar
• Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J. Neurooncol. 63, 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Bottomley A, Flechtner H, Efficace F et al. on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Data Center and Quality of Life Group. Health related quality of life outcomes in cancer clinical trials. Eur. J. Cancer 41(12), 1697–1709 (2005).
   PubMed Web of Science ®Google Scholar
• Groenvold M, Petersen M, Aaronson NK et al. for the EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur. J. Cancer (2005) (In Press).
   PubMedGoogle Scholar
• Davies E, Clarke C. Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. J. Neurol. Neurosurg. Psychiatry 76, 555–561 (2005).
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Linggood R, Wolfson L et al. Quality and duration of survival in glioblastoma multiforme. JAMA 241, 1016 (1979).
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology 30, 172–177 (1980).
   PubMed Web of Science ®Google Scholar
• Lieberman AN, Foo SH, Ransohoff J et al. Long-term survival among patients with malignant brain tumors. Neurosurgery 10, 450–453 (1982).
   PubMed Web of Science ®Google Scholar
• Maire JP, Coudin B, Guérin J, Caudry M. Neuropsychological impairment in adults with brain tumors. Am. J. Clin. Oncol. 10, 152–162 (1987).
   PubMed Web of Science ®Google Scholar
• Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann. Neurol. 28, 818–822 (1990).
   PubMed Web of Science ®Google Scholar
• Ammirati M, Vick N, Liao Y et al. Effect of the extent of surgical resection in survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21, 201–206 (1987).
   PubMed Web of Science ®Google Scholar
• Leibel SA, Gutin PH, Wara WM et al. Survival and quality of life after interstitial implantation of removable high-activity Iodine-125 for the treatment of patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 17, 1129–1139 (1989).
   PubMed Web of Science ®Google Scholar
• Sachsenheimer W, Piotrowski W, Bimmler T. Quality of life in patients with intracranial tumors on the basis of Karnofsky’s performance status. J. Neurooncol. 13, 177–181 (1992).
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Wallner K, Malkin MG. Good performance status of long-term disease-free survivors of intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 26, 129–133 (1993).
   PubMed Web of Science ®Google Scholar
• Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J. Neurooncol. 14, 243–253 (1992).
   PubMed Web of Science ®Google Scholar
• Archibald YM, Lunn D, Ruttan LA et al. Cognitive functioning in long-term survivors of high-grade glioma. J. Neurosurg. 80, 247–253 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Linzmayer L, Becherer A et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J. Neurooncol. 63, 55–61 (2003).
   PubMed Web of Science ®Google Scholar
• Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumor. J. Neurol. Neurosurg. Psychiatry 67, 358–363 (1999).
   PubMed Web of Science ®Google Scholar
• Klein M, Taphoorn MJB, Heimans JJ et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J. Clin. Oncol. 19, 4037–4047 (2001).
   PubMed Web of Science ®Google Scholar
• Salo J, Niemela A, Joukamaa M, Koivukangas J. Effect of brain tumour laterality on patients’ perceived quality of life. J. Neurol. Neurosurg. Psychiatry 72, 373–377 (2002).
   PubMed Web of Science ®Google Scholar
• Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade malignant glioma. J. Neurooncol. 34, 263–278 (1997).
   PubMed Web of Science ®Google Scholar
• Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiforme. Oncol. Nurs. Forum 26, 921–925 (1999).
   PubMedGoogle Scholar
• Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro. Oncol. 2, 221–228 (2000).
   PubMed Web of Science ®Google Scholar
• Giovagnoli AR, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J. Neurol. Neurosurg. Psychiatry 76, 562–568 (2005).
   PubMed Web of Science ®Google Scholar
• Efficace F, Bottomley A. Health-related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer. Eur. J. Cancer 38, 1824–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Trojanowski T, Peszynski J, Turowski K et al. Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J. Neurosurg. 70, 18–23 (1989).
   PubMed Web of Science ®Google Scholar
• Souhami L, Seiferheld W, Brachman D et al. Randomized comparison fo stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of RTOG 93–05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60, 853–860 (2004).
   Google Scholar
• Taylor BV, Buckner JC, Cascino TL. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J. Clin. Oncol. 16, 2195–2201 (1998).
   PubMed Web of Science ®Google Scholar
• Pickles T, Goodman GB, Rheaume DE et al. Pion radiation for high grade astrocytoma : results of a randomized study. Int. J. Radiat. Oncol. Biol. Phys. 37, 491–497 (1997).
   PubMed Web of Science ®Google Scholar
• Bampoe J, Laperriere N, Pintillie M, Glen J, Micallef J, Bernstein M. Quality of life in patients with glioblastoma multiforme participating in a randomized study of brachytherapy as a boost treatment. J. Neurosurg. 93, 917–926 (2000).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18, 1481–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259–266 (2001).
   PubMed Web of Science ®Google Scholar